Lupus Research Alliance meets the 20 Standards for Charity Accountability.
Lupus Research Alliance (LRA) works to find better treatments and prevent and cure systemic lupus erythematosus (SLE or lupus), an autoimmune disease, by supporting medical research. The organization reports that it supports biomedical research from basic science to novel concepts, translational and clinical research, and clinical proof of concept for new treatments. LRA also states that it develops partnerships with the healthcare and scientific community, grassroots community leaders, and people with lupus to increase advocacy efforts aimed at benefiting the international lupus community by raising awareness and increasing public funding for lupus research.
For the year ended December 31, 2020, Lupus Research Alliance's program expenses were:
Research |
$15,400,647 |
Scientific programs |
$12,839,966 |
Public policy |
$743,966 |
Total Program Expenses: |
$28,984,579 |
-
Chief Executive
Kenneth M. Farber, President and Chief Executive Officer
-
Compensation*
$503,095
-
Chair of the Board
Ira Akselrad
-
Chair's Profession / Business Affiliation
President, The Johnson Company
-
Board Size
27
-
Paid Staff Size
40
*2020 compensation includes annual salary and, if applicable, benefit plans, expense accounts, and other allowances.
Method(s) Used:
Direct mail appeals, Grant proposals, Internet, Invitations to fund raising events, Planned giving arrangements, Print advertisements (newspapers, magazines, etc.), Other
LRA incurred joint costs of $64,434 for informational materials and activities that included fundraising materials. Of those costs $51,547 was allocated to fundraising expenses and $12,887 was allocated to program expenses.
Fundraising costs were 7% of related contributions. (Related contributions, which totaled $41,539,746, are donations received as a result of fundraising activities.)
This organization is tax-exempt under section 501(c) (3) of the Internal Revenue Code.It is eligible to receive contributions deductible as charitable donations for federal income tax purposes.
The following information is based on Lupus Research Alliance's audited financial statements - consolidated for the year ended December 31, 2020.
Source of Funds |
Contributions |
$37,640,822 |
Investment income, net |
$7,827,115 |
Special events income, net |
$3,131,249 |
LuCIN consulting revenue |
$1,291,193 |
Walkathon income, net |
$767,675 |
Grants cancelled |
$219,700 |
Sublet income |
$20,119 |
Total Income |
$50,897,873 |
- Programs: 86%
- Fundraising: 8%
- Administrative: 6%
Total Income |
$50,897,873 |
Program expenses |
$28,984,579 |
Fundraising expenses |
$2,838,968 |
Administrative expenses |
$2,264,536 |
Other expenses |
$0 |
Total expenses: |
$34,088,083 |
Income in Excess of Expenses |
$16,809,790 |
Beginning Net Assets |
$44,770,201 |
Other Changes In Net Assets |
$-22,936 |
Ending Net Assets |
$61,557,055 |
Total Liabilities |
$41,851,086 |
Total Assets |
$103,408,141 |
Note: As noted in the above financial section, "other changes in net assets" refers to a loss on sale of donated land and building held for resale.